Karachi: Abbott Laboratories (Pakistan) Limited has announced a significant development on its corporate calendar, with a Board of Directors meeting scheduled for Thursday, February 20, 2025. The virtual meeting, set to commence at 11:15 a.m., will focus on evaluating the company’s Annual Accounts for the fiscal year ending December 31, 2024. This meeting marks a crucial step in Abbott Laboratories’ financial oversight and strategic planning.
In accordance with the Pakistan Stock Exchange (PSX) regulations, the company has declared a “Close Period” from February 13, 2025, to February 20, 2025. During this period, as stipulated by Clause 5.6.4 of PSX Regulations, no Director, CEO, or Executive of Abbott Laboratories (Pakistan) Limited is permitted to engage in any form of trading or dealing with the company’s shares, whether directly or indirectly. This measure ensures transparency and fairness in the market, safeguarding against any potential conflicts of interest.
The designated market category for Abbott Laboratories (Pakistan) Limited is the pharmaceutical sector, where the company continues to play a pivotal role in delivering healthcare solutions. According to information available from the Pakistan Stock Exchange (PSX), the company’s adherence to regulatory requirements reflects its commitment to maintaining the highest standards of corporate governance.
Stakeholders, especially TRT-3 Certificate Holders of the Exchange, have been duly informed of the upcoming meeting and the associated Close Period. The company’s proactive communication underscores its dedication to engaging with its shareholders and maintaining an open dialogue regarding its financial performance and strategic direction.